79 / 89
79
22.
Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S,
Spanedda R, et al. Long-term survival of stage I multiple
myeloma given chemotherapy just after diagnosis or at
progression of the disease: a multicentre randomized
study. Cooperative Group of Study and Treatment of
Multiple Myeloma. Br J Cancer 2000;82:1254-60.
23.
Bladé J, Dimopoulos M, Rosiñol L, Rajkumar SV, Kyle
RA. Smoldering (asymptomatic) multiple myeloma:
current diagnostic criteria, new predictors of outcome,
and follow-up recommendations. J Clin Oncol
2010;28:690-7.
24.
Dmoszynska A, Walter-Croneck A, Hus I, Grzasko N,
Manko J, Jedrzejczak WW, et al. The efficacy and safety of
the low-thalidomide dose CTD (cyclophosphamide,
thalidomide, dexamethasone) regimen in patients with
multiple myeloma--a report by the Polish Myeloma Study
Group. Leuk Res 2010;34:1330-5.
25.
Sidra G, Williams CD, Russell NH, Zaman S, Myers B,
Byrne
JL.
Combination
chemotherapy
with
cyclophosphamide, thalidomide and dexamethasone for
patients with refractory, newly diagnosed or relapsed
myeloma. Haematologica 2006;91:862-3.
26.
Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J,
Goldstone AH, et al. Low-dose thalidomide in
combination with oral weekly cyclophosphamide and
pulsed dexamethasone is a well-tolerated and effective
regimen in patients with relapsed and refractory multiple
myeloma. Br J Haematol 2005;129:763-70.
27.
García-Sanz R, González-Porras JR, Hernández JM, Polo-
Zarzuela M, Sureda A, Barrenetxea C, et al. The oral
combination of thalidomide, cyclophosphamide and
dexamethasone
(ThaCyDex)
is
effective
in
relapsed/refractory
multiple
myeloma. Leukemia
2004;18:856-63.